SG11202111473UA - Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof - Google Patents

Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof

Info

Publication number
SG11202111473UA
SG11202111473UA SG11202111473UA SG11202111473UA SG11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA SG 11202111473U A SG11202111473U A SG 11202111473UA
Authority
SG
Singapore
Prior art keywords
assessing
disease
risk
methods
detection kit
Prior art date
Application number
SG11202111473UA
Other languages
English (en)
Inventor
Wen-Hung Chung
Shuen-Iu Hung
Chuang-Wei Wang
Original Assignee
Chang Gung Memorial Hospital Linkou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chang Gung Memorial Hospital Linkou filed Critical Chang Gung Memorial Hospital Linkou
Publication of SG11202111473UA publication Critical patent/SG11202111473UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11202111473UA 2019-05-06 2019-05-06 Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof SG11202111473UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/085639 WO2020223867A1 (fr) 2019-05-06 2019-05-06 Procédé d'évaluation du risque de réactions cutanées à un médicament indésirables graves provoquées par des médicaments antirhumatismaux à modulation de maladie, son kit de test et son utilisation

Publications (1)

Publication Number Publication Date
SG11202111473UA true SG11202111473UA (en) 2021-11-29

Family

ID=73050684

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111473UA SG11202111473UA (en) 2019-05-06 2019-05-06 Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof

Country Status (7)

Country Link
US (1) US20220259655A1 (fr)
JP (1) JP7334263B2 (fr)
KR (1) KR20210149135A (fr)
CN (1) CN112513294A (fr)
CA (1) CA3137521A1 (fr)
SG (1) SG11202111473UA (fr)
WO (1) WO2020223867A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470513B2 (en) * 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
NZ597628A (en) 2006-05-11 2013-07-26 Academia Sinica Hla-b5801 allele associated with adverse drug reactions and methods for detecting such
CN102108382A (zh) * 2009-12-23 2011-06-29 上海主健生物工程有限公司 卡马西平致皮肤严重不良反应遗传检测
CN105039579B (zh) * 2011-06-23 2018-10-02 长庚医疗财团法人基隆长庚纪念医院 用hla等位基因评估抗癫痫药物苯妥英引发药物过敏反应的方法
CN104818316B (zh) * 2013-11-28 2018-09-21 复旦大学 用于筛查柳氮磺胺吡啶所致皮肤药物不良反应的人类白细胞抗原基因检测试剂盒
CN107574235A (zh) 2017-10-25 2018-01-12 广州和康医疗技术有限公司 一种柳氮磺胺吡啶不良反应风险snp位点检测方法及试剂盒
CN109355358A (zh) * 2018-10-22 2019-02-19 江苏美因康生物科技有限公司 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法

Also Published As

Publication number Publication date
JP2022531136A (ja) 2022-07-06
CN112513294A (zh) 2021-03-16
CA3137521A1 (fr) 2020-11-12
KR20210149135A (ko) 2021-12-08
JP7334263B2 (ja) 2023-08-28
US20220259655A1 (en) 2022-08-18
WO2020223867A1 (fr) 2020-11-12

Similar Documents

Publication Publication Date Title
IL270864A (en) Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders
GB2591361B (en) Methods and systems for determining a physiological or biological state or condition of a subject
EP3740567A4 (fr) Détection d'exosomes et de biomarqueurs exosomaux pour le diagnostic et le pronostic de maladies et de troubles
IL283845A (en) Methods for detecting diseases while using rna analysis
IL276893A (en) Systems and methods for detecting residual disease
EP3265588A4 (fr) Procédés pour évaluer le risque de survenue ou de récidive d'une maladie à l'aide d'informations relatives au niveau d'expression et à des variants de séquences
EP3399918A4 (fr) Systèmes et procédés de détermination d'indications cliniques
EP3289082A4 (fr) Procédés de séquençage, de détermination, d'appariement, et de validation d'agents thérapeutiques et d'antigènes spécifiques de maladies
IL288098A (en) Methods and systems for detecting disease residues
WO2016126972A8 (fr) Mutant smoothened et méthodes d'utilisation de celui-ci
EP3784397A4 (fr) Nouvel appareil et procédés de détection de maladie
MX2021003764A (es) Determinacion de trastornos de la motilidad de los intestinos y la vejiga, y de la fibromialgia.
WO2016205828A3 (fr) Rôle de la citrullination dans le diagnostic de maladies
MX2016009450A (es) Ensayo novedoso para detectar periostina humana.
EP3773195A4 (fr) Systèmes et procédés de mesure du corps sur la base d'une analyse d'image
BR112016029935A2 (pt) ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
IL279377A (en) Methods for assessment and early detection of stress, selection and monitoring of treatment and new use of drugs
EP3869198A3 (fr) Réactifs et procédés de détection du cancer du sein
FR3017703B1 (fr) Procede et systeme de determination de la compatibilite d'un guidage angulaire avec une approche
SG11202111473UA (en) Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof
EP4101379C0 (fr) Capsule et système de biocapteur
EP3278271A4 (fr) Procédé et appareil permettant d'identifier une personne grâce à la mesure des distances entre les parties du corps de cette personne
WO2015181804A3 (fr) Procédé et test de détection non invasive d'un cancer gastrique à un stade précoce par l'utilisation combinée d'adn sans cellule de reprimo méthylé et de pepsinogène i/ii
FR3020531B1 (fr) Dispositif et methode de determination du temps d'arrivee d'un signal uwb.
WO2015120075A3 (fr) Mutant smoothened et méthodes d'utilisation de celui-ci